FDA unveils changes to cancer drug review
September 14, 2011Research and Development, Sales and Marketing Cancer, FDA, regulatory affairs
The FDA has unveiled a reorganisation of how it reviews new cancer drugs, and says the new approach should help …
GSK-Amicus start late-stage trials of Fabry disease treatment
September 14, 2011Research and Development Amicus Therapeutics, Fabry disease, GSK
GlaxoSmithKline and Amicus Therapeutics are moving forward with their phase III programme for Fabry disease treatment Amigal. The first patient …
Novartis loses global development head to Gates Foundation
September 14, 2011Research and Development Bill and Melinda Gates Foundation, Novartis, appointment
Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill …
Government bites the bullet over A&E closure
September 14, 2011NHS, NHS reform, hosptials
The government has backed the closure of the Accident and Emergency department at Chase Farm hospital in London, ending years …
The recast of the Restriction of Hazardous Substances (RoHS) Directive
September 13, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The recast Directive on the Restriction of the Use of Certain Hazardous Substances in Electrical and Electronic Equipment (2011/65/EU) will …
Victoza data shows promise for early setting
September 13, 2011Research and Development, Sales and Marketing Novo Nordisk, Victoza
New data for Novo Nordisk’s Victoza could help the drug’s chances of being used in an earlier setting for type …
Betting big on research in China
September 13, 2011Manufacturing and Production, Research and Development China, R&D
For eighteen out of the last twenty centuries, China has stood as the world’s most innovative and largest economy – …
AM-Pharma appoints new chief executive
September 13, 2011Manufacturing and Production, Research and Development appointment, manufacturing and production, research and development
Dutch biopharmaceutical company AM-Pharma has appointed Erik van den Berg as its new chief executive. He was previously VP business …
Genzyme confirms further Fabrazyme delay
September 13, 2011Manufacturing and Production Fabrazyme, Genzyme, pharma manufacturing news
Genzyme has been forced to delay shipments of its Fabry disease treatment Fabrazyme once again, blaming its “quality release process”. …
Slow Provenge growth prompts Dendreon staff cull
September 13, 2011Business Services, Manufacturing and Production Dendreon, Provenge, job cuts, pharma manufacturing news
After months of building manufacturing capacity, US biotech Dendreon has decided to slash a quarter of its workforce – with …
Aurobindo forms Russian joint venture with Diod
September 13, 2011Manufacturing and Production, Sales and Marketing Aurobindo, Diod, pharma manufacturing news
Indian drugmaker Aurobindo has formed a joint venture with Russia’s OJSC Diod in order to tap into the local market …
Offshoring pharma manufacturing increases risk, says study
September 12, 2011Manufacturing and Production Puerto Rico, contract manufacturing, pharma manufacturing news
Drugs produced in offshore manufacturing plants – even those run by US manufacturers – pose a greater quality risk than …
Pharma manufacturing news in brief
September 12, 2011Manufacturing and Production pharma manufacturing news
DMV-Fonterra agrees to buy India’s Brahmar Cellulose, plus there are facility updates from Reliable and Toyoba, some bad press for …
Richard Head joins the Research Partnership
September 12, 2011Sales and Marketing appointment, sales and marketing
Market research company the Research Partnership has appointed Richard Head as a director. He will be based at the company’s …
FDA recommends Xarelto for new approval
September 12, 2011Sales and Marketing Xarelto, atrial fibrillation, stroke
FDA advisors have recommended Bayer and Johnson & Johnson’s Xarelto be approved in the US for the prevention of stroke …
GSK scales back breast cancer trial
September 12, 2011Research and Development, Sales and Marketing GSK, Tyverb
GSK has halted one of the four phase III studies that make up the ALTTO programme for its cancer drug …
Takeda moves potential first-in-class diabetes drug into phase III
September 12, 2011Research and Development, Sales and Marketing TAK-875, Takeda, diabetes
Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
Digital Pharma: Twitter slip-up shouldn’t silence pharma
September 9, 2011Medical Communications, Sales and Marketing Bayer, Code of Practice, Digital Pharma blog, PMCPA, Twitter
Bayer UK was recently ruled to have breached the ABPI Code of Practice by promoting prescription-only medicines to the general …
Pan appoints trio of new starters
September 9, 2011Medical Communications appointment, medical communications
Pan Advertising has appointed a trio of new starters across its creative and client services teams. Maneesh Sharma joins the …
Branding agency 1HQ appoints Burton Paul
September 9, 2011Medical Communications appointment, medical communications
Burton Paul has joined Windsor, UK-based branding agency 1HQ as client director to head up their health division. He has …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
